Sterilizing Parenteral Drug Containers with Nitrogen Dioxide - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sterilizing Parenteral Drug Containers with Nitrogen Dioxide
Room-temperature sterilization using nitrogen dioxide gas provides benefits for sterilizing the external surfaces of single-dose, parenteral drug containers.


Equipment and Processing Report

Nitrogen dioxide (NO2) gas can provide manufacturers of parenteral drug products with a truly room temperature means of sterilizing the external surfaces of single-dose drug containers that are intended for use in a sterile field.  Other sterilization options, such as ethylene oxide (EO), hydrogen peroxide (H2O2), and radiation, may expose the drug products to elevated temperatures over extended times or penetrate the container and closure systems. Both of these scenarios can adversely affect drug products or biologics, especially those that have limited stability at elevated temperatures. NO2 is compatible with many of the materials that are common to parenteral drug containers and closure systems including glass, cyclic olefin copolymers (COC), polypropylene, silicone rubber, thermoplastic elastomers, and pharmaceutical rubbers. As a surface sterilant, NO2 does not penetrate containers or closure systems during the sterilization process, leaving the drug product unaffected.

NO2 possesses some specific chemical and physical properties that make it well-positioned for use as a sterilant for pressure- and temperature-sensitive parenteral drug products. Because it boils at 21 °C, the NO2 sterilant can be introduced into the chamber with minimal to no vacuum.  Sterilization is typically carried out using NO2 concentrations that are in the range of 1–2% of the saturated vapor pressure. Because of this, condensation of the sterilant is not likely to occur, even in complicated geometries. Heating of the NO2 sterilization chamber is not required to maintain the sterilant gas phase, which allows sterilization and aeration to be carried out at room temperature. Both EO and H2O2 sterilization, however, generally require some degree of heating, which can result in destabilization of sensitive products.

NO2 sterilization provides rapid and effective inactivation of both vegetative and spore forms of bacteria. This rapid lethality allows a sterility assurance level of 10-6 to be achieved in a cycle with a typical door-to-door time of 60–120 minutes, thereby minimizing the time that the drug product is exposed to room temperature. There is no preconditioning phase, and aeration of residual sterilant from the product is included in the overall cycle time.

NO2 is compatible with many of the sterile barrier packaging options on the market, such as Tyvek pouches and plastic trays with Tyvek lids. As NO2 is a surface sterilant, the gas requires access to the product, which is afforded by the breathable Tyvek. Sterilization with NO2 would typically be carried out in the primary packaging, and any instructions for use would be included in the secondary package.

NO2 sterilant, while a toxic gas, is noncarcinogenic and nonflammable, which makes it attractive as an option to bring sterilization onto the manufacturing floor for higher volume manufacturers. In-house sterilization offers potential savings in terms of both transportation and inventory carrying costs associated with contract sterilization. Sterilization can be placed in-line between primary and final packaging operations. For manufacturers whose volumes are not large enough to warrant on-site sterilization, yet who require room-temperature sterilization, contract NO2 sterilization is an option.

Evan Goulet, PhD, is technical applications manager at Noxilizer, info@noxilizer.com.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
8%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Equipment and Processing Report,
Click here